Michael Duerr

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7866613/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A unique population of IgG-expressing plasma cells lacking CD19 is enriched in human bone marrow. Blood, 2015, 125, 1739-1748.	1.4	170
2	COVID-19 pandemic and worldwide organ transplantation: a population-based study. Lancet Public Health, The, 2021, 6, e709-e719.	10.0	139
3	Preemptive treatment of Cytomegalovirus infection in kidney transplant recipients with letermovir: results of a Phase 2a study. Transplant International, 2014, 27, 77-86.	1.6	125
4	The need for minimization strategies: current problems of immunosuppression. Transplant International, 2015, 28, 891-900.	1.6	104
5	A Randomized Clinical Trial of Anti–IL-6 Antibody Clazakizumab in Late Antibody-Mediated Kidney Transplant Rejection. Journal of the American Society of Nephrology: JASN, 2021, 32, 708-722.	6.1	101
6	Increased Incidence of Angioedema with ACE Inhibitors in Combination with mTOR Inhibitors in Kidney Transplant Recipients. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 703-708.	4.5	74
7	Exploring the Complexity of Death-Censored Kidney Allograft Failure. Journal of the American Society of Nephrology: JASN, 2021, 32, 1513-1526.	6.1	67
8	Clazakizumab in late antibody-mediated rejection: study protocol of a randomized controlled pilot trial. Trials, 2019, 20, 37.	1.6	48
9	Experience with belatacept rescue therapy in kidney transplant recipients. Transplant International, 2016, 29, 1184-1195.	1.6	46
10	Review of Bortezomib Treatment of Antibody-Mediated Rejection in Renal Transplantation. Antioxidants and Redox Signaling, 2014, 21, 2401-2418.	5.4	45
11	Multifrequency Magnetic Resonance Elastography for the Assessment of Renal Allograft Function. Investigative Radiology, 2016, 51, 591-595.	6.2	44
12	Conversion to Belatacept in Maintenance Kidney Transplant Patients. Transplantation, 2018, 102, 1545-1552.	1.0	43
13	Enteric-coated mycophenolate sodium. Expert Opinion on Drug Safety, 2010, 9, 981-994.	2.4	40
14	Assessment of the Kidney Donor Profile Index in a European cohort. Nephrology Dialysis Transplantation, 2018, 33, 1465-1472.	0.7	36
15	Identification of T Cell–Mediated Vascular Rejection After Kidney Transplantation by the Combined Measurement of 5 Specific MicroRNAs in Blood. Transplantation, 2016, 100, 898-907.	1.0	32
16	Biomarkers of Over-Immunosuppression. Clinical Pharmacology and Therapeutics, 2011, 90, 316-322.	4.7	31
17	Everolimus with cyclosporine withdrawal or low-exposure cyclosporine in kidney transplantation from Month 3: a multicentre, randomized trial. Nephrology Dialysis Transplantation, 2017, 32, 1060-1070.	0.7	31
18	Multiparametric Quantitative MRI for the Detection of IgA Nephropathy Using Tomoelastography, DWI, and BOLD Imaging. Investigative Radiology, 2019, 54, 669-674.	6.2	31

MICHAEL DUERR

#	Article	IF	CITATIONS
19	Transplanting HCV-Infected Kidneys into Uninfected Recipients. New England Journal of Medicine, 2017, 377, 1103-1105.	27.0	29
20	Identification and Therapeutic Management of Highly Sensitized Patients Undergoing Renal Transplantation. Drugs, 2012, 72, 1335-1354.	10.9	27
21	An evaluation of sirolimus in renal transplantation. Expert Opinion on Drug Metabolism and Toxicology, 2012, 8, 1337-1356.	3.3	26
22	Tomoelastography Paired With T2* Magnetic Resonance Imaging Detects Lupus Nephritis With Normal Renal Function. Investigative Radiology, 2019, 54, 89-97.	6.2	25
23	Dendritic cell–regulatory T ell interactions control selfâ€directed immunity. Immunology and Cell Biology, 2007, 85, 575-581.	2.3	23
24	Risk Evaluation and Outcome of Pneumocystis jirovecii Pneumonia in Kidney Transplant Patients. Transplantation Proceedings, 2016, 48, 2924-2930.	0.6	23
25	Comparison of ultrasound shear wave elastography with magnetic resonance elastography and renal microvascular flow in the assessment of chronic renal allograft dysfunction. Acta Radiologica, 2018, 59, 1139-1145.	1.1	23
26	Validation of the Living Kidney Donor Profile Index in a European cohort and comparison of long-term outcomes with US results. Nephrology Dialysis Transplantation, 2019, 34, 1063-1070.	0.7	23
27	Any Progress in the Treatment of Antibody-Mediated Rejection?. Journal of the American Society of Nephrology: JASN, 2018, 29, 350-352.	6.1	22
28	Immunologic outcome in elderly kidney transplant recipients: is it time for HLA-DR matching?. Nephrology Dialysis Transplantation, 2016, 31, 2143-2149.	0.7	21
29	No relevant pharmacokinetic interaction between pantoprazole and mycophenolate in renal transplant patients: a randomized crossover study. British Journal of Clinical Pharmacology, 2015, 80, 1086-1096.	2.4	16
30	Rituximab in Combination With Bortezomib, Plasmapheresis, and High-Dose IVIG to Treat Antibody-Mediated Renal Allograft Rejection. Transplantation Direct, 2016, 2, e91.	1.6	16
31	US Time-Harmonic Elastography for the Early Detection of Glomerulonephritis. Radiology, 2019, 292, 676-684.	7.3	15
32	Intensive blood pressure control is associated with improved patient and graft survival after renal transplantation. Scientific Reports, 2019, 9, 10507.	3.3	15
33	Treatment of Acute Antibody-Mediated Renal Allograft Rejection With Cyclophosphamide. Transplantation, 2017, 101, 2545-2552.	1.0	14
34	Extended-Spectrum Beta-Lactamase–Producing Enterobacteriaceae –Related Urinary Tract Infection in Kidney Transplant Recipients: Risk Factors, Treatment, and Long-Term Outcome. Transplantation Proceedings, 2017, 49, 1757-1765.	0.6	14
35	Impact of Pre-existing Comorbidities on Long-term Outcomes in Kidney Transplant Recipients. Transplantation Proceedings, 2018, 50, 3232-3241.	0.6	14
36	Onset and progression of diabetes in kidney transplant patients receiving everolimus or cyclosporine therapy: an analysis of two randomized, multicenter trials. BMC Nephrology, 2018, 19, 237.	1.8	14

MICHAEL DUERR

#	Article	IF	CITATIONS
37	Low Seroprevalence of SARS-CoV-2 Antibodies during Systematic Antibody Screening and Serum Responses in Patients after COVID-19 in a German Transplant Center. Journal of Clinical Medicine, 2020, 9, 3401.	2.4	13
38	Microvascular inflammation is a risk factor in kidney transplant recipients with very late conversion from calcineurin inhibitor-based regimens to belatacept. BMC Nephrology, 2020, 21, 354.	1.8	12
39	Five-year outcomes in kidney transplant patients randomized to everolimus with cyclosporine withdrawal or low-exposure cyclosporine versus standard therapy. American Journal of Transplantation, 2018, 18, 2965-2976.	4.7	11
40	Evaluation of histological dynamics, kidney function and diabetes in liver transplant patients after antiviral treatment with directâ€acting antivirals: Therapy of HCVâ€recurrence. Transplant Infectious Disease, 2019, 21, e13020.	1.7	11
41	New Perspectives of Immunosuppression. Transplantation Proceedings, 2013, 45, 1224-1231.	0.6	10
42	Clinical outcome of norovirus infection in renal transplant patients. Clinical Transplantation, 2016, 30, 1283-1293.	1.6	10
43	Incidence of Infectious Disease and Malignancies After Rituximab Therapy in Kidney Transplant Recipients: Results From a Cohort in Germany. Transplantation Proceedings, 2017, 49, 2269-2273.	0.6	10
44	Treatment of Antibody-Mediated Renal Allograft Rejection: Improving Step by Step. Journal of Immunology Research, 2017, 2017, 1-9.	2.2	10
45	Advances in pharmacotherapy to treat kidney transplant rejection. Expert Opinion on Pharmacotherapy, 2015, 16, 1627-1648.	1.8	9
46	Immunosuppression and Results in Renal Transplantation. European Urology Supplements, 2016, 15, 415-429.	0.1	9
47	Early conversion from cyclosporine to everolimus following living-donor kidney transplantation: outcomes at 5 years posttransplant in the randomized ZEUS trial. Clinical Nephrology, 2016, 85 (2016), 215-225.	0.7	9
48	Evaluation of severity of delayed graft function in kidney transplant recipients. Nephrology Dialysis Transplantation, 2022, 37, 973-981.	0.7	8
49	A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients. BMC Nephrology, 2019, 20, 36.	1.8	7
50	Antiâ€interleukinâ€6 antibody clazakizumab in late antibodyâ€mediated kidney transplant rejection: effect on cytochrome P450 drug metabolism. Transplant International, 2021, 34, 1542-1552.	1.6	7
51	Successful Recovery of Acute Renal Transplant Failure in Recurrent Hepatitis C Virus–Associated Membranoproliferative Glomerulonephritis. American Journal of Transplantation, 2017, 17, 819-823.	4.7	5
52	Predictors of graft survival at diagnosis of antibodyâ€mediated renal allograft rejection: a retrospective singleâ€center cohort study. Transplant International, 2020, 33, 149-160.	1.6	5
53	Tomoelastography for Longitudinal Monitoring of Viscoelasticity Changes in the Liver and in Renal Allografts after Direct-Acting Antiviral Treatment in 15 Kidney Transplant Recipients with Chronic HCV Infection. Journal of Clinical Medicine, 2021, 10, 510.	2.4	5
54	Pan-Genotype Pre-Exposure Prophylaxis (PrEP) Allows Transplantation of HCV-Positive Donor Kidneys to Negative Transplant Recipients. Journal of Clinical Medicine, 2021, 10, 89.	2.4	5

MICHAEL DUERR

#	Article	IF	CITATIONS
55	Initial Experience With SARS-CoV-2-Neutralizing Monoclonal Antibodies in Kidney or Combined Kidney-Pancreas Transplant Recipients. Transplant International, 2022, 35, 10109.	1.6	5
56	Influence of pretransplant class I and II non-donor-specific anti-HLA immunization on immunologic outcome and graft survival in kidney transplant recipients. Transplant Immunology, 2020, 63, 101333.	1.2	4
57	The relationship between proteinuria and allograft survival in patients with transplant glomerulopathy: a retrospective singleâ€center cohort study. Transplant International, 2021, 34, 259-271.	1.6	4
58	About Incidence and Timing of Donor-Specific Antibodies After Graft Nephrectomy. Transplantation, 2012, 93, 865-866.	1.0	3
59	Conversion to Belatacept based regimen does not change T-cell phenotype and function in renal transplantation. Transplant Immunology, 2015, 33, 176-184.	1.2	3
60	Pharmacokinetics of Daclatasvir, Sofosbuvir, and GS-331007 in a Prospective Cohort of Hepatitis C Virus–Positive Kidney Transplant Recipients. Therapeutic Drug Monitoring, 2019, 41, 53-58.	2.0	3
61	Analysis of Risk Factors and Long-Term Outcomes in Kidney Transplant Patients with Identified Lymphoceles. Journal of Clinical Medicine, 2020, 9, 2841.	2.4	3
62	The Renal Resistive Index in Allografts: Is Sonographic Assessment Sufficiently Reproducible in a Routine Clinical Setting? – Reproducibility of the Renal Resistive Index. RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren, 2020, 192, 561-566.	1.3	1
63	Focal Segmental Glomerulosclerosis and Recurrence in Living Donor Recipients. Research and Reports in Urology, 2021, Volume 13, 495-499.	1.0	1
64	Clinicopathologic Features and Risk Factors of Proteinuria in Transplant Glomerulopathy. Frontiers in Medicine, 2021, 8, 666319.	2.6	1
65	MO105TELEMEDICAL SURVEILLANCE AND OPTIMIZED TREATMENT OF BLOOD PRESSURE IN KIDNEY TRANSPLANT RECIPIENTS. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0